Purpose – The purpose of this paper is to aggregate significant part of debates in the field of International Non-Governmental Organizations (INGOs) toward performance improvement by benchmarking of the Total Quality Management (TQM) practices, and to propose TQM-Benchmarking model as a seed for future research in the context of INGOs. Design/methodology/approach – TQM practices for INGOs were first identified based on critical synthesis of the literature for both, existing for-profit TQM literature and the INGOs field-specific quality and accountability frameworks, initiatives, and practices (Jordan introduced as an example) followed by solicitation of the opinions of experts and colleagues through personal interviews and focus group discussions to define the proposed TQM-Benchmarking model. Findings – TQM-Benchmarking model of six practices vital to INGOs performance are proposed by this review including leadership and management commitment, beneficiaries focus and participation, partnership management for sustainability, human resource (HR) focus, process management and learning and continuous improvement, and use of quality information. Originality/value – While TQM practices succeed in improving performance of for-profit organizations, this review proposed TQM-Benchmarking model with field-specific practical pillars of performance improvement in the INGOs.

The price elasticity estimates suggest that significant increases in tobacco taxes are likely to be effective in reducing smoking in Jordan, particularly smoking among men.

No abstract

Purpose The purpose of this paper is to establish practical guidelines for benchmarking eight total quality management (TQM) practices vital to pharmaceutical companies’ performance. The paper also proposes the use of an analytic total quality index (TQI) as a benchmarking tool and illustrates the importance and effectiveness of this benchmarking methodology by applying it in two comparative studies of three Jordanian pharmaceutical companies. Design/methodology/approach In order to achieve the above-mentioned purpose, the data were gathered through a questionnaire that was used to evaluate the gap between the ideal and current status of the quality management system and distributed to the quality units from three companies: pharmaceutical manufacturing company, a pharmaceutical manufacturing company working in the same field and a pharmaceutical service providing research services to a pharmaceutical manufacturing companies. And the mean differences between the current and ideal states for the eight critical TQM practices were compared for these two comparative studies using the t-test. Findings Each of the two comparisons reveals statistically significant differences regarding the perceptions of actual and ideal scores for manufacturing and service companies on five out of eight critical factors and, on two out of eight critical factors for manufacturing and manufacturing companies. Practical implications The pharmaceutical companies, regardless of whether they are manufacturing or service company, can adopt benchmarking techniques which were applied in this case study to improve their performance and their product/service quality. Originality/value The consequences of this research can support organization managers and policy makers in effectively benchmarking the identified TQM practices in their organizations using the proposed TQI benchmarking tool.

Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.